Tag Archives: FRI

FRI technology used in PhD thesis on hyperinflation and COPD exacerbations

Last October, Wouter van Geffen, pulmonologist at the Medical Center Leeuwarden, The Netherlands, was awarded his PhD degree for this thesis titled: Hyperinflation and COPD exacerbations.

In chapter four of this dissertation, the heterogeneity of acute COPD exacebations was investigated using Functional Respiratory Imaging (FRI).

COPD exacerbations are a major burden to patients and yet little is understood about their heterogeneity. This contributes to a current persistent one-size-fits all treatment. New insights are required in order to replace this by more personalized, precision medicine. 

In this study, functional respiratory imaging proved to be a useful tool to get better insight into COPD exacerbations. Significant improvements in its indices can be demonstrated from the acute phase to resolution even in relatively small groups. FRI clearly visualized the marked variability in ventilation and resistance during exacerbations within and between individuals and it can also be used as a tool to assess the heterogeneity of COPD exacerbations.

FRI shows clinically meaningful benefits of Bevespi in COPD

We are happy to announce that a few days ago the positive results of AstraZeneca’s Bevespi (LABA/LAMA), compared to placebo have been published in the International Journal of COPD. The study shows how FRI confirmed the strong, homogeneous effect of the innovative co-suspension bronchodilator compared to placebo, as seen in earlier studies. At the same… Continue Reading

A randomized study using FRI to characterize bronchodilator effects of glycopyrrolate formoterol fumarate delivered by a metered dose inhaler using co-suspension delivery technology in patients with COPD

Int J Chron Obstruct Pulmon Dis. 2018 Aug 30;13:2673-2684. Authors De Backer W, De Backer J, Vos W, Verlinden I, Van Holsbeke C, Clukers J, Hajian B, Siddiqui S, Jenkins M, Reisner C, Martin UJ. Read more Continue Reading

How is FRI a solution to your research question?

How is FRI a solution to your research question?

  We’ve said it before: the respiratory field is the most expensive one in the pharmaceutical world. The low sensitivity of several clinical biomarkers make it difficult for therapy developers to limit the size of their trails. Similarly, in the clinical domain, high costs occur among others from insensitive or difficult measurements, late detection of… Continue Reading

I:E and breathing control in CF drug delivery – what makes or breaks treatment?

  Cystic fibrosis (CF) is a devastating, chronic disease that affects over 100,000 people worldwide. The consequences patients need to bear with them for the rest of their lives are even more devastating. A CF patient is signed for continuous care, daily treatments, hours of daily physiotherapy sessions and regular hospital check-ups or visits, next… Continue Reading

Fluidda NV

Groeningenlei 132

2550 Kontich

Belgium

BE 0877 160 706

Tel: +32/(0)3 450 87 20

Fax: +32/(0)3 450 87 29

info@fluidda.com

Fluidda NV

Groeningenlei 132

2550 Kontich

Belgium

BE 0877 160 706

Tel: +32/(0)3 450 87 20

Fax: +32/(0)3 450 87 29

info@fluidda.com

FLUIDDA, Inc

675 US Highway One
North Brunswick, NJ 08902
United States

FLUIDDA, Inc

675 US Highway One
North Brunswick, NJ 08902
United States

FLUIDDA India

Medical Imaging pvt ltd
A-95/96, DGP Nagar -2, Ambad
Nashik 422010
India

FLUIDDA India

Medical Imaging pvt ltd
A-95/96, DGP Nagar -2, Ambad
Nashik 422010
India

All content © FLUIDDA 2019